Advancing PRAME pMHC Targeted T-Cell Engager for Solid Tumor Therapy
- Bispecific T‑cell engagers have shown strong clinical success in hematologic cancers, but their use in solid tumors is limited by the lack of antigens that are sufficiently selective to avoid on‑target, off‑tumor toxicity
- PRAME, a cancer‑testis antigen with highly tumor‑restricted expression, was identified as a promising solid‑tumor TCE target, and the PRAME₄₂₅ peptide presented by MHC‑I was validated as an attractive pMHC epitope for selective targeting
- Novel antiPRAME₄₂₅ pMHC antibodies were discovered that specifically recognize the PRAME₄₂₅–MHC complex without binding to MHC alone or unrelated pMHCs, and when formatted into TCEs, they drive PRAME₄₂₅specific tumor cell killing—establishing a new class of antiPRAME pMHC biologics